EDAP TMS Jumps on Cancer Study Success

Michael Teague |

EDAP Jumps on Cancer Study SuccessEDAP TMS SA (EDAP), a French company that develops “minimally invasive therapeutic solutions for urology”, saw their share prices leap as much as over 34 percent on Friday to a high of $3.89 per share.

The strong performance follows the announcement of extremely encouraging results of a long-term study that showed high rates of both cancer survival as well as avoidance of salvage therapy.  704 patients treated for localized prostate cancer with high-intensity focused ultrasound therapy, otherwise known as HIFU, over a 15-year period (between 1995 and 2009) at the Munich-Harlaching clinic in southern Germany.

With 78.5 percent of the men studied having intermediate or high-risk prostate cancer, the study demonstrated a cancer-specific survival-rate of 98 percent, while rescue therapy (the kind given to a patient who does not respond to standard treatment) was avoided 99 percent of the time with low-risk patients, 72 percent of the time for those at medium-risk, and in 68 percent of cases involving high-risk patients.

In other words, the HIFU treatment was shown to be effective not only in fighting prostate cancer, but it was also very effective in precluding the need for potentially destructive salvage treatments.  Dr. Stefan Thuroff, the Vice Chairman of the Department of Urology for the clinic claimed that the authors of the study agreed that 15 years of data “may warrant the possible closing of the investigational phase of whole gland HIFU. The confidence this study provides in the ability to ablate prostate cancer may also encourage the use of focal therapy”, suggesting that EDAP’s Ablatherm-HIFU may be extended to treat other related types of cancer.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
EDAP EDAP TMS S.A. 2.98 -0.05 -1.65 50,232
BDN Brandywine Realty Trust 15.35 0.13 0.85 507,183

Comments

Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

8tracks

Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…